Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...